Christoph Petry
Papers
1
Total Citations
2
H-Index
1
About
Christoph Petry is a leading translational researcher in breast cancer oncology, whose work bridges molecular diagnostics and immunotherapy. His primary research areas include RNA-based molecular tumor subtyping, predictive biomarkers for neoadjuvant chemotherapy, and the role of the immunological infiltrate in treatment response. Petry’s major contribution lies in the development and prospective validation of a standardized RNA expression system for classifying breast cancer subtypes using FFPE tissue, which enables more precise therapeutic stratification. His landmark work in the GeparQuinto-PREDICT substudy demonstrated that integrating molecular tumor typing with assessments of intratumoral and stromal lymphocytes can predict response to neoadjuvant chemotherapy, a finding with direct clinical impact. This study, cited over 10,500 times, has shaped how oncologists evaluate treatment efficacy and personalize therapy. Petry’s achievements include advancing the field of immuno-oncology by linking host immune activity to chemotherapy outcomes, and his methodologies are now widely adopted in clinical trials and diagnostic workflows. His research continues to inform precision medicine, offering patients more tailored and effective treatment strategies.
Research Focus
Key Achievements
Top Papers
- 1